
Pool A
Diabetes Subgroup
Placebo (N=50)
Completed 43 (86.0%)
Discontinued 7 (14.0%)
Reason for Discontinuation
Adverse Event 2 (4.0%)
Major Protocol Deviation 1 (2.0%)
Lost to Follow-up 2 (4.0%)
Voluntary Withdrawal 0 (0.0%)
Lack of Efficacy 1 (2.0%)
Other 1 (2.0%)
AZL-M 40 mg (N=127)
Completed 118 (92.9%)
Discontinued 9 (7.1%)
Reason for Discontinuation
Adverse Event 2 (1.6%)
Major Protocol Deviation 1 (0.8%)
Lost to Follow-up 1 (0.8%)
Voluntary Withdrawal 1 (0.8%)
Lack of Efficacy 2 (1.6%)
Other 2 (1.6%)
AZL-M 80 mg (N=109)
Completed 101 (92.7%)
Discontinued 8 (7.3%)
Reason for Discontinuation
Adverse Event 1 (0.9%)
Major Protocol Deviation 2 (1.8%)
Lost to Follow-up 2 (1.8%)
Voluntary Withdrawal 1 (0.9%)
Lack of Efficacy 2 (1.8%)
Other 0 (0.0%)
Olmesartan 40 mg (N=96)
Completed 92 (95.8%)
Discontinued 4 (4.2%)
Reason for Discontinuation
Adverse Event 0 (0.0%)
Major Protocol Deviation 0 (0.0%)
Lost to Follow-up 2 (2.1%)
Voluntary Withdrawal 0 (0.0%)
Lack of Efficacy 1 (1.0%)
Other 1 (1.0%)
Pre Diabetes Subgroup
Placebo (N=133)
Completed 125 (94.0%)
Discontinued 8 (6.0%)
Reason for Discontinuation
Adverse Event 2 (1.5%)
Major Protocol Deviation 2 (1.5%)
Lost to Follow-up 1 (0.8%)
Voluntary Withdrawal 0 (0.0%)
Lack of Efficacy 3 (2.3%)
Other 0 (0.0%)
AZL-M 40 mg (N=231)
Completed 215 (93.1%)
Discontinued 16 (6.9%)
Reason for Discontinuation
Adverse Event 5 (2.2%)
Major Protocol Deviation 2 (0.9%)
Lost to Follow-up 3 (1.3%)
Voluntary Withdrawal 3 (1.3%)
Lack of Efficacy 3 (1.3%)
Other 0 (0.0%)
AZL-M 80 mg (N=216)
Completed 199 (92.1%)
Discontinued 17 (7.9%)
Reason for Discontinuation
Adverse Event 5 (2.3%)
Major Protocol Deviation 0 (0.0%)
Lost to Follow-up 2 (0.9%)
Voluntary Withdrawal 8 (3.7%)
Lack of Efficacy 0 (0.0%)
Other 2 (0.9%)
Olmesartan 40 mg (N=243)
Completed 227 (93.4%)
Discontinued 16 (6.6%)
Reason for Discontinuation
Adverse Event 5 (2.1%)
Major Protocol Deviation 0 (0.0%)
Lost to Follow-up 1 (0.4%)
Voluntary Withdrawal 4 (1.6%)
Lack of Efficacy 4 (1.6%)
Other 2 (0.8%)
Non Diabetes Subgroup
Placebo (N=114)
Completed 103 (90.4%)
Discontinued 11 (9.6%)
Reason for Discontinuation
Adverse Event 5 (4.4%)
Major Protocol Deviation 2 (1.8%)
Lost to Follow-up 0 (0.0%)
Voluntary Withdrawal 1 (1.9%)
Lack of Efficacy 3 (2.6%)
Other 0 (0.0%)
AZL-M 40 mg (N=203)
Completed 185 (91.1%)
Discontinued 18 (8.9%)
Reason for Discontinuation
Adverse Event 3 (1.5)%
Major Protocol Deviation 1 (0.5%)
Lost to Follow-up 1 (0.5%)
Voluntary Withdrawal 7 (3.4%)
Lack of Efficacy 3 (1.5)%
Other 3 (1.5)%
AZL-M 80 mg (N=243)
Completed 216 (88.9%)
Discontinued 27 (11.1%)
Reason for Discontinuation
Adverse Event 9 (3.7%)
Major Protocol Deviation 2 (0.8%)
Lost to Follow-up 3 (1.2%)
Voluntary Withdrawal 8 (3.3%)
Lack of Efficacy 3 (1.2%)
Other 2 (0.8%)
Olmesartan 40 mg (N=233)
Completed 217 (93.1%)
Discontinued 16 (6.9%)
Reason for Discontinuation
Adverse Event 5 (2.1%)
Major Protocol Deviation 0 (0.0%)
Lost to Follow-up 3 (1.3%)
Voluntary Withdrawal 4 (1.7%)
Lack of Efficacy 2 (0.9%)
Other 2 (0.9%)


Pool B
Diabetes Subgroup
AZL-M 40 mg (N=123)
Completed 104 (84.6%)
Discontinued 19 (15.4%)
Reason for Discontinuation
Adverse Event 4 (3.3%)
Major Protocol Deviation 1 (0.8%)
Lost to Follow-up 4 (3.3%)
Voluntary Withdrawal 4 (3.3%)
Lack of Efficacy 3 (2.4%)
Other 3 (2.4%)
AZL-M 80 mg (N=124)
Completed 106 (85.5%)
Discontinued 18 (14.5%)
Reason for Discontinuation
Adverse Event 4 (3.2%)
Major Protocol Deviation 1 (0.8%)
Lost to Follow-up 3 (2.4%)
Voluntary Withdrawal 5 (4.0%)
Lack of Efficacy 2 (1.6%)
Other 3 (2.4%)
Valsartan (N=123)
Completed 95 (77.2%)
Discontinued 28 (22.8%)
Reason for Discontinuation
Adverse Event 6 (4.9%)
Major Protocol Deviation 0 (0.0%)
Lost to Follow-up 3 (2.4%)
Voluntary Withdrawal 6 (4.9%)
Lack of Efficacy 11 (8.9%)
Other 2 (1.6%)
Pre Diabetes Subgroup
AZL-M 40 mg (N=236)
Completed 194 (82.2%)
Discontinued 42 (17.8%)
Reason for Discontinuation
Adverse Event 7 (3.0%)
Major Protocol Deviation 3 (1.3%)
Lost to Follow-up 5 (2.1%)
Voluntary Withdrawal 13 (5.5%)
Missing 1 (0.4%)
Lack of Efficacy 10 (4.2%)
Other 3 (1.3%)
AZL-M 80 mg (N=220)
Completed 175 (79.5%)
Discontinued 45 (20.5%)
Reason for Discontinuation
Adverse Event 15 (6.8%)
Major Protocol Deviation 2 (0.9%)
Lost to Follow-up 4 (1.8%)
Voluntary Withdrawal 14 (6.4%)
Missing 0 (0.0%)
Lack of Efficacy 6 (2.7%)
Other 4 (1.8%)
Valsartan (N=238)
Completed 198 (83.2%)
Discontinued 40 (16.8%)
Reason for Discontinuation
Adverse Event 12 (5.0%)
Major Protocol Deviation 2 (0.8%)
Lost to Follow-up 6 (2.5%)
Voluntary Withdrawal 11 (4.6%)
Missing 0 (0.0%)
Lack of Efficacy 8 (3.4%)
Other 1 (0.4%)
Non Diabetes Subgroup
AZL-M 40 mg (N=248)
Completed 208 (83.9%)
Discontinued 40 (16.1%)
Reason for Discontinuation
Adverse Event 16 (6.5%)
Major Protocol Deviation 2 (0.8%)
Lost to Follow-up 4 (1.6%)
Voluntary Withdrawal 9 (3.6%)
Lack of Efficacy 6 (2.4%)
Other 3 (1.2%)
AZL-M 80 mg (N=269)
Completed 223 (82.9%)
Discontinued 46 (17.1%)
Reason for Discontinuation
Adverse Event 16 (5.9%)
Major Protocol Deviation 1 (0.4%)
Lost to Follow-up 11 (4.1%)
Voluntary Withdrawal 14 (5.2%)
Lack of Efficacy 2 (0.7%)
Other 2 (0.7%)
Valsartan (N=242)
Completed 205 (84.7%)
Discontinued 37 (15.3%)
Reason for Discontinuation
Adverse Event 9 (3.7%)
Major Protocol Deviation 1 (0.4%)
Lost to Follow-up 4 (1.7%)
Voluntary Withdrawal 10 (4.1%)
Lack of Efficacy 11 (4.5%)
Other 2 (0.8%)